This report provides a comprehensive analysis of the global urokinase injection market, projecting steady growth from 2025 through 2032. It examines the clinical use of this clot-dissolving therapy across various applications, including pulmonary embolism, deep vein thrombosis, and catheter occlusion clearance. Key market dynamics include the rise of catheter-dependent patient populations and shifting procedural trends in vascular care. The study further evaluates competitive landscapes, regional demand, and segmentation by dosage, administration approach, and purity levels.

Market Overview

Market Size and Growth Projections

The global Urokinase Injection market is projected to grow from US$ 306 million in 2025 to US$ 472 million by 2032. The market is expected to expand at a Compound Annual Growth Rate (CAGR) of 6.5% from 2026 to 2032.

Product Definition and Mechanism of Action

Urokinase injection refers to the clinical and commercial use of injectable urokinase (urokinase for injection), a "clot-dissolving" medicine utilized in hospital settings to break down unwanted blood clots.

• Mechanism: Urokinase acts on the body’s natural fibrinolytic system by converting plasminogen into plasmin. The resulting plasmin breaks down fibrin clots and also affects fibrinogen and various other plasma proteins.
• Clinical Administration: Due to the requirement for injection/infusion and the potential for serious bleeding, use is typically restricted to highly monitored clinical environments, including:
• Emergency departments
• Intensive care units (ICUs)
• Catheter labs
• Interventional radiology suites
• Vascular surgery wards
• Specialized stroke or thrombosis centers

Market Positioning and Supply Chain

Unlike oral anticoagulants used for long-term prevention, urokinase injection serves as a time-sensitive rescue therapy or a procedure-support drug used when a clot poses an acute risk or blocks a medical device.

• Clinical Applications: In certain jurisdictions, product labeling and clinical practice include use for:
• Pulmonary embolism (blood clots in the lungs)
• Catheter-directed thrombolysis in peripheral arteries or graft occlusions
• Restoring the patency of intravenous catheters blocked by clotted blood or fibrin
• Dosage Form and Manufacturing: Products are commonly supplied as a sterile lyophilized (freeze-dried) powder requiring reconstitution before use. This necessitates complex upstream management of:
• Cell culture
• Purification
• Sterile fill-finish
• Strict quality control to ensure lot consistency and supply reliability

Industry Statistics (2025)

• Global Production Volume: Approximately 15.6 million Units
• Average Global Market Price: Approximately US$ 20.1 per Unit
• Single-Line Production Capacity: 350 to 500 K Units per year
• Industry Gross Profit Margin: Approximately 25%-35%

Market Trends

1. Evolution of Thrombolysis Pathways

Thrombolysis is being shaped by newer agents, improved imaging, and increased interventional procedures.

• Stroke Segment "Two-Track" Trend:
• In many regions, practice is consolidating around intravenous alteplase, tenecteplase, and mechanical thrombectomy pathways.
• In other regions, urokinase remains highly relevant due to its cost-effectiveness, local availability, and established evidence bases. For example, in China, intravenous urokinase is recommended within specific time windows for acute ischemic stroke (with commonly cited dosing ranges of 1,000,000–1,500,000 IU).

2. Expansion of Catheter-Related Opportunities

The increasing use of central venous catheters and long-term lines for chemotherapy, parenteral nutrition, IV antibiotics, and repeated blood draws has expanded the market for catheter-clearance thrombolytics. As the patient population dependent on long-term catheters rises (including cancer care, home infusion, complex pediatrics, and dialysis), hospitals are placing higher value on reliable, fast methods to reopen lines and avoid replacement procedures.

3. Shift Toward Targeted Vascular Therapy

There is a procedural shift toward catheter-directed approaches to localize treatment at the clot, aiming to improve efficacy while limiting systemic exposure and bleeding risk. While urokinase has a history in catheter-directed settings, it faces intense competition from:

• Other Thrombolytics: Alteplase, tenecteplase, and reteplase.
• Mechanical Strategies: Aspiration, thrombectomy devices, and angioplasty/stenting.

This competition drives the urokinase market toward specific niches where it offers operational or economic advantages, such as cost, protocol familiarity, or suitability for specific catheter-clearance workflows.

Market Segmentation

By Type

• 10000-100000IU
• 100000-1000000IU
• Others

By Clinical Use

• Pulmonary Embolism Thrombolysis
• Deep Vein Thrombosis
• Peripheral Arterial Occlusion Thrombolysis
• Catheter / Cannula Occlusion Clearance
• Others

By Administration Approach

• Systemic Infusion
• Catheter-directed Thrombolysis (CDT)
• Intracatheter Dwell / Lock Technique

By Purity

• Standard Clinical Grade
• High-purity / Low-impurity Grade
• Low Endotoxin / Low Bioburden Specifications

By Application

• Hospital
• Clinic
• Others

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Vendors

• Syner-Med
• Wanhua Biochem
• Jiangxi Haoran Bio-Pharma
• Jiangsu Aidea Pharmaceutical
• Techpool
• Microbic Biosystems
• LIVZON
• Wuhan Humanwell Pharma
• Tianjin Biochem Pharma

About the Report

This research report, "Urokinase Injection Industry Forecast" by LP Information, Inc. (LPI), provides a comprehensive analysis of the global Urokinase Injection landscape. It reviews total world sales in 2025 and provides projected sales analysis for 2026 through 2032, broken down by region, market sector, and sub-sector.

Key Analysis Areas:

• Product segmentation, company formation, revenue, and market share.
• Latest developments and M&A activity.
• Leading company strategies (portfolios, capabilities, market entry, and geographic footprints).
• Market trends, drivers, and affecting factors.

Key Questions Addressed

• What is the 10-year outlook for the global Urokinase Injection market?
• What factors are driving Urokinase Injection market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Urokinase Injection market opportunities vary by end market size?
• How does Urokinase Injection break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Urokinase Injection Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Urokinase Injection by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Urokinase Injection by Country/Region, 2021, 2025 & 2032

  • 2.2 Urokinase Injection Segment by Type

    • 2.2.1 10000-100000IU

    • 2.2.2 100000-1000000IU

    • 2.2.3 Others

    • 2.2.4 Urokinase Injection Sales by Type

      • 2.2.4.1 Global Urokinase Injection Sales Market Share by Type (2021-2026)
      • 2.2.4.2 Global Urokinase Injection Revenue and Market Share by Type (2021-2026)
      • 2.2.4.3 Global Urokinase Injection Sale Price by Type (2021-2026)

  • 2.3 Urokinase Injection Segment by Clinical Use

    • 2.3.1 Pulmonary Embolism Thrombolysis

    • 2.3.2 Deep Vein Thrombosis

    • 2.3.3 Peripheral Arterial Occlusion Thrombolysis

    • 2.3.4 Catheter / Cannula Occlusion Clearance

    • 2.3.5 Others

    • 2.3.6 Urokinase Injection Sales by Clinical Use

      • 2.3.6.1 Global Urokinase Injection Sales Market Share by Clinical Use (2021-2026)
      • 2.3.6.2 Global Urokinase Injection Revenue and Market Share by Clinical Use (2021-2026)
      • 2.3.6.3 Global Urokinase Injection Sale Price by Clinical Use (2021-2026)

  • 2.4 Urokinase Injection Segment by Administration Approach

    • 2.4.1 Systemic Infusion

    • 2.4.2 Catheter-directed Thrombolysis (CDT)

    • 2.4.3 Intracatheter Dwell / Lock Technique

    • 2.4.4 Urokinase Injection Sales by Administration Approach

      • 2.4.4.1 Global Urokinase Injection Sales Market Share by Administration Approach (2021-2026)
      • 2.4.4.2 Global Urokinase Injection Revenue and Market Share by Administration Approach (2021-2026)
      • 2.4.4.3 Global Urokinase Injection Sale Price by Administration Approach (2021-2026)

  • 2.5 Urokinase Injection Segment by Purity

    • 2.5.1 Standard Clinical Grade

    • 2.5.2 High-purity / Low-impurity Grade

    • 2.5.3 Low Endotoxin / Low Bioburden Specifications

    • 2.5.4 Urokinase Injection Sales by Purity

      • 2.5.4.1 Global Urokinase Injection Sales Market Share by Purity (2021-2026)
      • 2.5.4.2 Global Urokinase Injection Revenue and Market Share by Purity (2021-2026)
      • 2.5.4.3 Global Urokinase Injection Sale Price by Purity (2021-2026)

  • 2.6 Urokinase Injection Segment by Application

    • 2.6.1 Hospital

    • 2.6.2 Clinic

    • 2.6.3 Others

    • 2.6.4 Urokinase Injection Sales by Application

      • 2.6.4.1 Global Urokinase Injection Sale Market Share by Application (2021-2026)
      • 2.6.4.2 Global Urokinase Injection Revenue and Market Share by Application (2021-2026)
      • 2.6.4.3 Global Urokinase Injection Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Urokinase Injection Breakdown Data by Company

    • 3.1.1 Global Urokinase Injection Annual Sales by Company (2021-2026)

    • 3.1.2 Global Urokinase Injection Sales Market Share by Company (2021-2026)

  • 3.2 Global Urokinase Injection Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Urokinase Injection Revenue by Company (2021-2026)

    • 3.2.2 Global Urokinase Injection Revenue Market Share by Company (2021-2026)

  • 3.3 Global Urokinase Injection Sale Price by Company

  • 3.4 Key Manufacturers Urokinase Injection Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Urokinase Injection Product Location Distribution

    • 3.4.2 Players Urokinase Injection Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Urokinase Injection by Geographic Region

  • 4.1 World Historic Urokinase Injection Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Urokinase Injection Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Urokinase Injection Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Urokinase Injection Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Urokinase Injection Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Urokinase Injection Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Urokinase Injection Sales Growth

  • 4.4 APAC Urokinase Injection Sales Growth

  • 4.5 Europe Urokinase Injection Sales Growth

  • 4.6 Middle East & Africa Urokinase Injection Sales Growth

• 5 Americas

  • 5.1 Americas Urokinase Injection Sales by Country

    • 5.1.1 Americas Urokinase Injection Sales by Country (2021-2026)

    • 5.1.2 Americas Urokinase Injection Revenue by Country (2021-2026)

  • 5.2 Americas Urokinase Injection Sales by Type (2021-2026)

  • 5.3 Americas Urokinase Injection Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Urokinase Injection Sales by Region

    • 6.1.1 APAC Urokinase Injection Sales by Region (2021-2026)

    • 6.1.2 APAC Urokinase Injection Revenue by Region (2021-2026)

  • 6.2 APAC Urokinase Injection Sales by Type (2021-2026)

  • 6.3 APAC Urokinase Injection Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Urokinase Injection by Country

    • 7.1.1 Europe Urokinase Injection Sales by Country (2021-2026)

    • 7.1.2 Europe Urokinase Injection Revenue by Country (2021-2026)

  • 7.2 Europe Urokinase Injection Sales by Type (2021-2026)

  • 7.3 Europe Urokinase Injection Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Urokinase Injection by Country

    • 8.1.1 Middle East & Africa Urokinase Injection Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Urokinase Injection Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Urokinase Injection Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Urokinase Injection Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Urokinase Injection

  • 10.3 Manufacturing Process Analysis of Urokinase Injection

  • 10.4 Industry Chain Structure of Urokinase Injection

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Urokinase Injection Distributors

  • 11.3 Urokinase Injection Customer

• 12 World Forecast Review for Urokinase Injection by Geographic Region

  • 12.1 Global Urokinase Injection Market Size Forecast by Region

    • 12.1.1 Global Urokinase Injection Forecast by Region (2027-2032)

    • 12.1.2 Global Urokinase Injection Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Urokinase Injection Forecast by Type (2027-2032)

  • 12.7 Global Urokinase Injection Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Syner-Med

    • 13.1.1 Syner-Med Company Information

    • 13.1.2 Syner-Med Urokinase Injection Product Portfolios and Specifications

    • 13.1.3 Syner-Med Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Syner-Med Main Business Overview

    • 13.1.5 Syner-Med Latest Developments

  • 13.2 Wanhua Biochem

    • 13.2.1 Wanhua Biochem Company Information

    • 13.2.2 Wanhua Biochem Urokinase Injection Product Portfolios and Specifications

    • 13.2.3 Wanhua Biochem Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Wanhua Biochem Main Business Overview

    • 13.2.5 Wanhua Biochem Latest Developments

  • 13.3 Jiangxi Haoran Bio-Pharma

    • 13.3.1 Jiangxi Haoran Bio-Pharma Company Information

    • 13.3.2 Jiangxi Haoran Bio-Pharma Urokinase Injection Product Portfolios and Specifications

    • 13.3.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Jiangxi Haoran Bio-Pharma Main Business Overview

    • 13.3.5 Jiangxi Haoran Bio-Pharma Latest Developments

  • 13.4 Jiangsu Aidea Pharmaceutical

    • 13.4.1 Jiangsu Aidea Pharmaceutical Company Information

    • 13.4.2 Jiangsu Aidea Pharmaceutical Urokinase Injection Product Portfolios and Specifications

    • 13.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Jiangsu Aidea Pharmaceutical Main Business Overview

    • 13.4.5 Jiangsu Aidea Pharmaceutical Latest Developments

  • 13.5 Techpool

    • 13.5.1 Techpool Company Information

    • 13.5.2 Techpool Urokinase Injection Product Portfolios and Specifications

    • 13.5.3 Techpool Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Techpool Main Business Overview

    • 13.5.5 Techpool Latest Developments

  • 13.6 Microbic Biosystems

    • 13.6.1 Microbic Biosystems Company Information

    • 13.6.2 Microbic Biosystems Urokinase Injection Product Portfolios and Specifications

    • 13.6.3 Microbic Biosystems Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Microbic Biosystems Main Business Overview

    • 13.6.5 Microbic Biosystems Latest Developments

  • 13.7 LIVZON

    • 13.7.1 LIVZON Company Information

    • 13.7.2 LIVZON Urokinase Injection Product Portfolios and Specifications

    • 13.7.3 LIVZON Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 LIVZON Main Business Overview

    • 13.7.5 LIVZON Latest Developments

  • 13.8 Wuhan Humanwell Pharma

    • 13.8.1 Wuhan Humanwell Pharma Company Information

    • 13.8.2 Wuhan Humanwell Pharma Urokinase Injection Product Portfolios and Specifications

    • 13.8.3 Wuhan Humanwell Pharma Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Wuhan Humanwell Pharma Main Business Overview

    • 13.8.5 Wuhan Humanwell Pharma Latest Developments

  • 13.9 Tianjin Biochem Pharma

    • 13.9.1 Tianjin Biochem Pharma Company Information

    • 13.9.2 Tianjin Biochem Pharma Urokinase Injection Product Portfolios and Specifications

    • 13.9.3 Tianjin Biochem Pharma Urokinase Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Tianjin Biochem Pharma Main Business Overview

    • 13.9.5 Tianjin Biochem Pharma Latest Developments

• 14 Research Findings and Conclusion